Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform

26 Feb, 2021

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform
Photo by Dose Media on Unsplash

– Cullgen Inc. closed a $50m Series B financing (assuming exercise of warrant).
– The round was led by 3E Bioventures Capital, as well as Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital and South China Venture Capital.
– The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases.
– Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.
– Cullgen is also pleased to announce that Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.

Biotechnology North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: